Resistance to carbapenems is increasing worldwide, leading to ever more restricted therapeutic choices (
1). In
Pseudomonas aeruginosa, resistance to β-lactams is mostly due to overproduction of the chromosome-encoded cephalosporinase, to cell wall impermeability, to alteration of the outer membrane protein OprD, or to overexpression of efflux pumps, often in association with the aforementioned mechanisms or with the acquisition of β-lactamases through horizontal gene transfer (HGT) (
2). Several class B carbapenemases (i.e., VIM, IMP, NDM, and SPM) and to a lesser extent certain class A carbapenemases (i.e., GES and KPC) have been involved in the carbapenem resistance of
P. aeruginosa (
2–5). Since these carbapenemases are acquired transferable resistance determinants, they have the greatest clinical impact in hospitals worldwide (
1,
4). Although they have been frequently observed in
Enterobacteriaceae with OXA-48 and in
Acinetobacter baumannii with OXA-23, OXA-40, OXA-58, and OXA-143, carbapenem-hydrolyzing class D β-lactamases (CHDLs) have been observed very rarely in
P. aeruginosa, To the best of our knowledge, OXA-40 was detected in two clonally unrelated, imipenem-resistant, clinical isolates in Spain, OXA-48- and OXA-181-producing
P. aeruginosa strains were isolated in India and in the United Kingdom (from a patient repatriated from India), respectively, and a novel CHDL, OXA-198, that belongs to a new group of class D β-lactamases was observed in a clinical isolate of
P. aeruginosa in Belgium (
6–10). In this work, we have characterized three additional OXA-198-producing
P. aeruginosa isolates, along with their plasmids harboring the
blaOXA-198 gene.